ArticleMicrobial cell factories2020
Efficient protection of microorganisms for delivery to the intestinal tract by cellulose sulphate encapsulation.
Article in Microbial cell factories, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 44 citations in OpenAlex.
- Biotechnological Potential of Quorum Quenching Bacterial Strains Isolated fromAnimals : an open access journal from MDPI · 2026Article
- Article
- Next-Generation Microencapsulation Technologies for Probiotic Protection and Precision Delivery.Microbial biotechnology · 2026Review
- Artificial polysaccharide-binding protein mediates co-assembly of nanodrug and probiotics against drug-resistant infectious enteritis.Asian journal of pharmaceutical sciences · 2025Article
- Hypoglycemic, Antioxidant Activities, and Probiotic Characteristics ofLife (Basel, Switzerland) · 2025Article
- Probiotic Potential ofMicroorganisms · 2025Article
- Review
- Review
- Microbiome engineering: unlocking therapeutic potential in inflammatory bowel disease.Frontiers in microbiology · 2025Review
- Review
- Electrospinning Microencapsulation ofMicroorganisms · 2023Article
- Survivability of freeze- and spray-dried probiotics and their effects on the growth and health performance of broilers.Veterinary world · 2023Article
- Supplementation of microencapsulated probiotics modulates gut health and intestinal microbiota.Food science & nutrition · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGut microbiota in humans and animals play an important role in health, aiding in digestion, regulation of the immune system and protection against pathogens. Changes or imbalances in the gut microbiota (dysbiosis) have been linked to a variety of local and systemic diseases, and there is growing evidence that restoring the balance of the microbiota by delivery of probiotic microorganisms can improve health. However, orally delivered probiotic microorganisms must survive transit through lethal highly acid conditions of the stomach and bile salts in the small intestine. Current methods to protect probiotic microorganisms are still not effective enough.
resultsWe have developed a cell encapsulation technology based on the natural polymer, cellulose sulphate (CS), that protects members of the microbiota from stomach acid and bile. Here we show that six commonly used probiotic strains (5 bacteria and 1 yeast) can be encapsulated within CS microspheres. These encapsulated strains survive low pH in vitro for at least 4 h without appreciable loss in viability as compared to their respective non-encapsulated counterparts. They also survive subsequent exposure to bile. The CS microspheres can be digested by cellulase at concentrations found in the human intestine, indicating one mechanism of release. Studies in mice that were fed CS encapsulated autofluorescing, commensal E. coli demonstrated release and colonization of the intestinal tract.
conclusionTaken together, the data suggests that CS microencapsulation can protect bacteria and yeasts from viability losses due to stomach acid, allowing the use of lower oral doses of probiotics and microbiota, whilst ensuring good intestinal delivery and release.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.